Abstract |
The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported. The effects of adding rituximab to CODOX-M/IVAC have not been published either. Fifteen consecutive patients with a median age of 39 years were treated with modified CODOX-M/IVAC regimen (particularly, reducing the dose of methotrexate to 3 g/m(2)) with or without rituximab at our institution. Although all patients developed grade 4 neutropenia and grade 3/4 thrombocytopenia/ anemia, 93% had febrile neutropenia, 60% showed transaminase elevation, and 40% had mucositis/ stomatitis (all grade 3), there were no treatment-related deaths. Two of nine patients treated with rituximab developed biphasic late-onset neutropenia. Thirteen patients (87%) showed complete responses. The remaining two patients had refractory disease; one had presented with peritoneal dissemination and complex chromosomal abnormalities, while the other had double IGH-MYC and IGH-BCL2 translocations. The estimated 5-year overall and progression-free survival were 87% each, with a median follow-up of 74 months. In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.
|
Authors | Dai Maruyama, Takashi Watanabe, Akiko Miyagi Maeshima, Junko Nomoto, Hirokazu Taniguchi, Teruhisa Azuma, Masakazu Mori, Wataru Munakata, Sung-Won Kim, Yukio Kobayashi, Yoshihiro Matsuno, Kensei Tobinai |
Journal | International journal of hematology
(Int J Hematol)
Vol. 92
Issue 5
Pg. 732-43
(Dec 2010)
ISSN: 1865-3774 [Electronic] Japan |
PMID | 21120644
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
- Cytarabine
- Rituximab
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Ifosfamide
- Methotrexate
|
Topics |
- Adult
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Burkitt Lymphoma
(drug therapy, pathology)
- Cyclophosphamide
(administration & dosage)
- Cytarabine
(administration & dosage)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Humans
- Ifosfamide
(administration & dosage)
- Lymphoma, B-Cell
(drug therapy, pathology)
- Male
- Methotrexate
(administration & dosage)
- Middle Aged
- Rituximab
- Treatment Outcome
- Vincristine
(administration & dosage)
- Young Adult
|